Cytokinetics, Incorporated (CYTK): A Bull Case Theory 

We came across a bullish thesis on Cytokinetics, Incorporated on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on CYTK. Cytokinetics, Incorporated’s share was trading at $65.16 as of February 2nd.

Cytokinetics (CYTK) is a late-stage biopharma focused on developing drugs that target the sarcomere, specifically cardiac myosin, to treat debilitating muscle diseases. Its pipeline is concentrated on three...